Category Press Releases

Charles River Partners with Arovella Therapeutics on NGS Services

Charles River Laboratories Partners with Arovella Therapeutics to Advance GMP Next-Generation Sequencing for CAR-iNKT Cell Therapy Development Charles River Laboratories International, Inc. has announced a strategic collaboration with Arovella Therapeutics Ltd. to provide Good Manufacturing Practice (GMP)-compliant Next Generation Sequencing…

Read MoreCharles River Partners with Arovella Therapeutics on NGS Services

Cognito Therapeutics Presents New Biomarker Data at AAIC 2026

Cognito Therapeutics Presents New Biomarker Findings Highlighting Potential Mechanism of Spectris™ Neuromodulation for Alzheimer’s Disease Cognito Therapeutics, a clinical-stage neurotechnology company focused on developing innovative therapies for neurodegenerative diseases, has unveiled new exploratory biomarker findings that provide additional insight into…

Read MoreCognito Therapeutics Presents New Biomarker Data at AAIC 2026

Teva and Polpharma Biologics Forge Global Licensing Deal for an Ocrevus® (ocrelizumab) Biosimilar Candidate for Multiple Sclerosis

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd, and Polpharma Biologics International AG announced a global licensing agreement granting Teva…

Read MoreTeva and Polpharma Biologics Forge Global Licensing Deal for an Ocrevus® (ocrelizumab) Biosimilar Candidate for Multiple Sclerosis

Octave MSDA Test Distinguishes True MS Relapse from Pseudoexacerbation

Octave MSDA Test Proven Effective in Identifying True MS Relapse Octave Bioscience, a commercial-stage precision neurology company focused on advancing personalized care for multiple sclerosis (MS) and other neurodegenerative disorders, has announced the publication of new independent research demonstrating the…

Read MoreOctave MSDA Test Distinguishes True MS Relapse from Pseudoexacerbation

Signatera™ MRD Test Predicts Survival Benefit from Chemotherapy in Metastatic Colorectal Cancer

Signatera™ MRD Test Predicts Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer Natera, Inc., a global leader in cell-free DNA testing and precision medicine, has announced the publication of new clinical data in JAMA Oncology demonstrating the potential…

Read MoreSignatera™ MRD Test Predicts Survival Benefit from Chemotherapy in Metastatic Colorectal Cancer

Arima Genomics Partners with Active Motif to Expand Hi-C Sequencing Access

Arima Genomics Partners with Active Motif to Expand Access to Hi-C Research Technologies While Accelerating Clinical Cancer Diagnostics Strategy Arima Genomics, Inc., a biotechnology company focused on advancing precision oncology through innovative cancer diagnostics, has announced a new strategic distribution…

Read MoreArima Genomics Partners with Active Motif to Expand Hi-C Sequencing Access

US Heart & Vascular Announces Georgia Expansion Through Two Cardiology Partnerships

US Heart and Vascular Expands Georgia Presence Through Partnerships with Cardiovascular Clinic of North Georgia and Cardiology of Atlanta US Heart and Vascular, a national provider of administrative and operational support services for independent cardiovascular physician practices, has announced strategic…

Read MoreUS Heart & Vascular Announces Georgia Expansion Through Two Cardiology Partnerships

Arcturus Therapeutics Partners with Thermo Fisher to Advance ARCT-032 for Cystic Fibrosis

Arcturus Therapeutics and Thermo Fisher Scientific Form Strategic Collaboration to Advance ARCT-032 for Cystic Fibrosis Through Phase 3 Development and Potential Commercialization Arcturus Therapeutics Holdings Inc., a clinical-stage messenger RNA (mRNA) medicines company focused on developing innovative therapies for liver…

Read MoreArcturus Therapeutics Partners with Thermo Fisher to Advance ARCT-032 for Cystic Fibrosis